Key facts
- It has raised $150.0M across 3 recorded rounds; the latest was Later Stage VC (Series C) ($150.0M) in Jul 2024.
- 1 institutional filer reports fund marks on Scorpion Therapeutics across 15 filings.
- Scorpion Therapeutics has filed 3 Form Ds with the SEC since 2020, most recently Jul 2024 ($125.7M sold to 38 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·Watchlist + deal alerts for Scorpion Therapeutics
Create free account
No card required
Funding rounds
3 roundsJul 2024Later Stage VC (Series C)$150.0M▮
About Scorpion Therapeutics
- Industry
- Drug Discovery
PA Mark — not yet priced
Scorpion Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Scorpion Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
1 filers · latest May 20261 SEC-registered fund reported 15 fair-value marks on Scorpion Therapeutics between May 2025 and May 2026. Filer-level marks and implied $/share are available to Pro members.